$SBFM +12.50% on today's news - Sunshine Biopharma Signs An Agreement With A Montreal-Based Company To Advance The Development Of Adva-27a Anticancer Compound
MONTREAL, QC / ACCESSWIRE / November 18, 2020 / Sunshine Biopharma Inc. (OTCPINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has entered into a collaboration agreement with Montreal-based company for the purposes of advancing the development of Sunshine Biopharma's anticancer compound, Adva-27a. The goal of this collaboration is to develop and implement chemical synthesis procedures for Adva-27a and test the resulting material in various types of cancer cells grown in culture. Based on the cell culture results, Sunshine's drug development partner will conduct mice studies in preparation for entry of Adva-27a into clinical trials. It is anticipated that the clinical trials will be for Stage IV pancreatic cancer indication and will be performed at McGill University's Jewish General Hospital in Montreal, Canada.